Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
EDITORIAL
Ann M Gillenwater, Nadarajah Vigneswaran, Andrew G Sikora
No abstract text is available yet for this article.
April 18, 2024: Journal of Clinical Oncology
#2
JOURNAL ARTICLE
Chengcheng Yan, Melissa A Richard, Christopher J Gibson, Jianbo He, Alysia Bosworth, David K Crossman, Purnima Singh, Lindsey Hageman, Rashi Kalra, Saro H Armenian, Julie Vose, Daniel J Weisdorf, Benjamin L Ebert, Yutaka Yasui, Stephen J Forman, Ravi Bhatia, Smita Bhatia
PURPOSE: Therapy-related myeloid neoplasm (t-MN) is a life-threatening complication of autologous peripheral blood stem cell transplantation (aPBSCT) for Hodgkin lymphoma (HL). Although previous studies have reported an association between clonal hematopoiesis (CH) in the infused PBSC product and subsequent post-aPBSCT risk of t-MN in patients with non-HL, information about patients with HL treated with aPBSCT is not available. METHODS: We constructed a retrospective cohort of 321 patients with HL transplanted at a median age of 34 years (range, 18-71)...
April 18, 2024: Journal of Clinical Oncology
#3
JOURNAL ARTICLE
Christopher A Barker, Suzanne Dufault, Sarah T Arron, Alan L Ho, Alain P Algazi, Lara A Dunn, Audrey A Humphries, Carter Hultman, Ming Lian, P Daniel Knott, Sue S Yom
PURPOSE: Locally advanced, unresectable basal cell carcinoma (LA BCC) can be treated with radiation therapy (RT), but locoregional control (LRC) rates are unsatisfactory. Vismodegib is a hedgehog pathway inhibitor (HPI) active in BCC that may radiosensitize BCC. We evaluated the combination of vismodegib and RT for patients with LA BCC. METHODS: In this multicenter, single-arm, phase II study, patients with unresectable LA BCC received 12 weeks of induction vismodegib, followed by 7 weeks of concurrent vismodegib and RT...
April 17, 2024: Journal of Clinical Oncology
#4
JOURNAL ARTICLE
Douglas E Peterson, Nicole L Stout, Lawrence N Shulman, Jennifer Perkins, Gabrielle LeMarier, Larissa Nekhlyudov
Delivery of high-quality, evidence-based oral care for those living with and beyond cancer needed!
April 17, 2024: Journal of Clinical Oncology
#5
(no author information available yet)
No abstract text is available yet for this article.
April 16, 2024: Journal of Clinical Oncology
#6
REVIEW
Nicholas Mikolajewicz, Patricia P Yee, Debarati Bhanja, Mara Trifoi, Alexandra M Miller, Philippe Metellus, Stephen J Bagley, Leonora Balaj, Leonardo J M de Macedo Filho, Brad E Zacharia, Dawit Aregawi, Michael Glantz, Michael Weller, Manmeet S Ahluwalia, Thomas Kislinger, Alireza Mansouri
Effective diagnosis, prognostication, and management of CNS malignancies traditionally involves invasive brain biopsies that pose significant risk to the patient. Sampling and molecular profiling of cerebrospinal fluid (CSF) is a safer, rapid, and noninvasive alternative that offers a snapshot of the intracranial milieu while overcoming the challenge of sampling error that plagues conventional brain biopsy. Although numerous biomarkers have been identified, translational challenges remain, and standardization of protocols is necessary...
April 12, 2024: Journal of Clinical Oncology
#7
JOURNAL ARTICLE
Anne Tierens, Nira Arad-Cohen, Daniel Cheuk, Barbara De Moerloose, Jose Maria Fernandez Navarro, Henrik Hasle, Kirsi Jahnukainen, Kristian Løvvik Juul-Dam, Gertjan Kaspers, Zanna Kovalova, Birgitte Lausen, Ulrika Norén-Nyström, Josefine Palle, Ramune Pasauliene, Cornelis Jan Pronk, Kadri Saks, Bernward Zeller, Jonas Abrahamsson
PURPOSE: Measurable residual disease (MRD) by using flow cytometry after induction therapy is strongly prognostic in pediatric AML, and hematopoietic stem-cell transplant (hSCT) may counteract a poor response. We designed a phase III study with intensified response-guided induction and MRD-based risk stratification and treated poor induction response with hSCT. The efficacy of liposomal daunorubicin (DNX) in induction was compared with mitoxantrone. METHODS: The study planned to randomly assign 300 patients, but the production of DNX ceased in 2017...
April 11, 2024: Journal of Clinical Oncology
#8
JOURNAL ARTICLE
Sarah Alexander, John A Kairalla, Sumit Gupta, Emily Hibbitts, Hannah Weisman, Doralina Anghelescu, Naomi J Winick, Kevin R Krull, Wanda L Salzer, Michael J Burke, Lia Gore, Meenakshi Devidas, Leanne Embry, Elizabeth A Raetz, Stephen P Hunger, Mignon L Loh, Kristina K Hardy
PURPOSE: Many children treated for ALL develop long-term neurocognitive impairments. Increased risk of these impairments is associated with treatment and demographic factors. Exposure to anesthesia is an additional possible risk factor. This study evaluated the impact of cumulative exposure to anesthesia on neurocognitive outcomes among a multicenter cohort of children with ALL. METHODS: This study was embedded in AALL1131, a Children's Oncology Group phase III trial for patients with high-risk B-ALL...
April 11, 2024: Journal of Clinical Oncology
#9
JOURNAL ARTICLE
Alejandro Ríos-Hoyo, Erin Cobain, Laura A Huppert, Peter D Beitsch, Thomas A Buchholz, Laura Esserman, Laura J van 't Veer, Hope S Rugo, Lajos Pusztai
No abstract text is available yet for this article.
April 9, 2024: Journal of Clinical Oncology
#10
JOURNAL ARTICLE
Massimo Federico, Wouter Plattel, Martin Hutchings, Yana Stepanishyna, Catherine Fortpied, Marc André
No abstract text is available yet for this article.
April 9, 2024: Journal of Clinical Oncology
#11
LETTER
Theodoros P Vassilakopoulos, Athanasios Liaskas, Patricio Pereyra, Andrea Gallamini
No abstract text is available yet for this article.
April 9, 2024: Journal of Clinical Oncology
#12
JOURNAL ARTICLE
Chao Cao, Lin Yang, Kathryn H Schmitz, Jennifer A Ligibel
PURPOSE: To examine the prevalence and cancer-specific patterns of functional disabilities among US cancer survivors. METHODS: Data from 47,768 cancer survivors and 2,432,754 noncancer adults age 18 years and older from the 2017 to 2022 Behavioral Risk Factor Surveillance System were analyzed. Functional disabilities assessed included mobility disability (ie, serious difficulty walking or climbing stairs) and self-care disability (ie, self-reported difficulty dressing or bathing)...
April 4, 2024: Journal of Clinical Oncology
#13
JOURNAL ARTICLE
Neil S Horowitz, Wei Deng, Ivy Peterson, Robert S Mannel, Spencer Thompson, Elizabeth Lokich, Tashanna Myers, Parvis Hanjani, David M O'Malley, Ki Young Chung, David S Miller, Frederick R Ueland, Don S Dizon, Austin Miller, Jyoti S Mayadev, Charles A Leath, Bradley J Monk
PURPOSE: To assess efficacy and toxicity of cisplatin (C) and gemcitabine (G) with intensity-modulated radiation therapy (IMRT) in patients with locally advanced vulvar cancer not amenable to surgery. METHODS: Patients enrolled in a single-arm phase II study. Pretreatment inguinal-femoral nodal assessment was performed. Sixty-four Gy IMRT was prescribed to the vulva, with 50-64 Gy delivered to the groins/low pelvis. Radiation therapy (RT) plans were quality-reviewed pretreatment...
April 4, 2024: Journal of Clinical Oncology
#14
JOURNAL ARTICLE
Wei Dai, Yaqin Wang, Jia Liao, Xing Wei, Zhen Dai, Wei Xu, Yangjun Liu, Xin Shelley Wang, Cecilia Pompili, Hongfan Yu, Yang Pu, Yuqian Zhao, Bangrong Cao, Qifeng Wang, Wenhong Feng, Yuanqiang Zhang, Fang Liu, Yuanle Deng, Jin Zhou, Juan Li, Shaohua Xie, Run Xiang, Xiang Wang, Bo Tian, Xiaozun Yang, Bin Hu, Xiaoqin Liu, Tianpeng Xie, Xiaojun Yang, Xiang Zhuang, Guibin Qiao, Qiang Li, Qiuling Shi
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We previously reported superior symptom control of electronic patient-reported outcome (ePRO)-based symptom management after lung cancer surgery for up to 1 month postdischarge...
April 4, 2024: Journal of Clinical Oncology
#15
JOURNAL ARTICLE
Carmine Valenza, Dario Trapani, Sibylle Loibl, Stephen K L Chia, Harold J Burstein, Giuseppe Curigliano
pCR should be integrated with other prognostic factors to optimize postneoadjuvant treatments in BC.
April 3, 2024: Journal of Clinical Oncology
#16
JOURNAL ARTICLE
Nam H Nguyen, Elissa B Dodd-Eaton, Jessica L Corredor, Jacynda Woodman-Ross, Sierra Green, Angelica M Gutierrez, Banu K Arun, Wenyi Wang
PURPOSE: There exists a barrier between developing and disseminating risk prediction models in clinical settings. We hypothesize that this barrier may be lifted by demonstrating the utility of these models using incomplete data that are collected in real clinical sessions, as compared with the commonly used research cohorts that are meticulously collected. MATERIALS AND METHODS: Genetic counselors (GCs) collect family history when patients (ie, probands) come to MD Anderson Cancer Center for risk assessment of Li-Fraumeni syndrome, a genetic disorder characterized by deleterious germline mutations in the TP53 gene...
April 3, 2024: Journal of Clinical Oncology
#17
LETTER
Yao Yu, Emily Miao, Luke R G Pike
No abstract text is available yet for this article.
April 3, 2024: Journal of Clinical Oncology
#18
JOURNAL ARTICLE
Pasi A Jänne, David Planchard, Kunihiko Kobayashi, James Chih-Hsin Yang
No abstract text is available yet for this article.
April 3, 2024: Journal of Clinical Oncology
#19
JOURNAL ARTICLE
Huabin Hu, Jianwei Zhang, Yunfeng Li, Xiaozhong Wang, Ziqiang Wang, Hui Wang, Liang Kang, Ping Liu, Ping Lan, Xiaojian Wu, Yunhuan Zhen, Haiping Pei, Zhongcheng Huang, Hao Zhang, Wenbin Chen, Yongming Zeng, Jiajun Lai, Hongbo Wei, Xuefeng Huang, Jiansi Chen, Jigui Chen, Kaixiong Tao, Qingwen Xu, Xiang Peng, Junlin Liang, Guanfu Cai, Kefeng Ding, Zhijie Ding, Ming Hu, Wei Zhang, Bo Tang, Chuyuan Hong, Jie Cao, Zonghai Huang, Wuteng Cao, Fangqian Li, Xinhua Wang, Chao Wang, Yan Huang, Yandong Zhao, Yue Cai, Jiayu Ling, Xiaoyu Xie, Zehua Wu, Lishuo Shi, Li Ling, Hao Liu, Jianping Wang, Meijin Huang, Yanhong Deng
PURPOSE: The role of neoadjuvant chemotherapy (NAC) in colon cancer remains unclear. This trial investigated whether 3 months of modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or capecitabine and oxaliplatin (CAPOX) as NAC could improve outcomes in patients with locally advanced colon cancer versus upfront surgery. PATIENTS AND METHODS: OPTICAL was a randomized, phase III trial in patients with clinically staged locally advanced colon cancer (T3 with extramural spread into the mesocolic fat ≥5 mm or T4)...
April 2, 2024: Journal of Clinical Oncology
#20
JOURNAL ARTICLE
Robert W Mutter, Cynthia Chauhan, Matthew P Goetz, Jean L Wright
No abstract text is available yet for this article.
April 2, 2024: Journal of Clinical Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
